Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting
February 25 2020 - 9:59AM
Business Wire
Enzo Biochem (NYSE:ENZ) announced preliminary results of voting
at the 2019 Annual Shareholder meeting held today.
According to these preliminary results, shareholders did not
approve the proposal to increase the size of Board, voted to elect
Fabian Blank, Peter Clemens and Rebecca Fischer to the Board of
Directors, approved the non-binding advisory resolution on
executive compensation, ratified the appointment of Enzo’s
independent registered public accounting firm and approved the
By-Law amendment to implement a majority voting standard in
uncontested director elections.
“We thank our shareholders for their participation in this
year’s shareholder meeting and welcome Fabian and Peter to the
Board of Directors. We look forward to working collectively with
our new colleagues, along with our strong management team, to
create shareholder value at Enzo,” said Dr. Elazar Rabbani,
Chairman and CEO of Enzo Biochem.
The final results will be reported on a Form 8-K that will be
filed with the Securities and Exchange Commission (SEC) once they
have been certified by the independent inspector of elections.
Forward-Looking Statements
Except for historical information, the matters discussed in this
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such statements include declarations regarding the intent, belief
or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2019. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225005697/en/
Elliot Sloane ESPR LLC Elliot.espr@gmail.com 917-291-0833
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024